# Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer

> **NCT00506623** · PHASE2 · UNKNOWN · sponsor: **National Cancer Center, Korea** · enrollment: 48 (actual)

## Conditions studied

- Rectal Neoplasm
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Capecitabine, Irinotecan

## Key facts

- **NCT ID:** NCT00506623
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2008-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2007-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506623, "Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00506623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*